JM-CTA collaboration | EAACI.org

Activities

JM-CTA collaboration

The JM board is delighted to continue its collaboration with the Clinical and Translational Allergy (CTA) journal (www.ctajournal.com) for the upcoming 2017-2019 term. The new JM-CTA Collaboration team consists of Carmen Riggioni (JM CTA collaboration coordinator), Claudia Bussolino, (CTA Facebook activities), Alessandra Arcolaci (CTA Twitter activities), Alberto Alvarez-Perea (JM secretary), Ibon Eguiluz-Gracia (JM Chair) and Olympia Tsilochristou (JM Chair past chair and current EAACI social media coordinator).

CTA is the freshest of the EAACI journals, offering distinctive characteristics. Open-access and an exclusively web-based presence, are both highly appealing to JMs worldwide, adding value to the JM-CTA relationship. JMs have worked closely with the Editorial Office of CTA to develop new initiatives for promotion of the journal and its educational activities for a younger audience.

CTA eagerly receives contributions of EAACI JMs, including clinical research, basic science original research and a wide range of reviews. In past years, the collaboration introduced a call for “Hot topic Reviews” written by JMs alongside prominent seniors allowing young researchers and clinicians to gain international visibility.

An important part of the collaboration is the monthly "JM Must read articles" which is selected by the JM-CTA team as the paper that is most relevant to fellows in training for its educational content, they are highlighted with the EAACI_JM logo in the online version of the journal.

The promotion of CTA journal in social media channels has increased its online posts and their impact. Be the first to know when a new article is published by following the hashtag #CTA_Journal. Have quick and free access via EAACI Twitter and Facebook links, to stay updated on the latest news on the allergy field. Come and follow us on Facebook and Twitter!

There are new and existing initiatives for the upcoming term. At the beginning of 2017, a call for reviewers was successfully launched with the help of the JM team. Also, EAACI is offering JMs, ten 50% discounts for processing charge on selected manuscripts published in CTA this year. Therefore, consider CTA for your original research and state-of-the-art reviews on topics of importance for clinicians and academics and remember that CTA open access policy can increase the impact of your paper.

CTA continues to gain presence as a reference journal for clinicians and scientists in the allergy field. We are thrilled to contribute with the ongoing success of CTA journal and congratulate the editors and CTA team for recently achieving an impact factor of 3.239. We strongly encourage all JMs to take an active role in following, reading and publishing in this forthcoming open access journal.


Best regards,

The JM-CTA Collaboration Team

Carmen Riggioni, Claudia Bussolino, Alessandra Arcolaci, Ibon Eguiluz-Gracia, Alberto Alvarez-Perea Alberto, Olympia Tsilochristou, (JM), Clive Grattan, Jean Bousquet and Holly Young (CTA)

Last updated 21 February 2018
Privacy Policy - disclaimer

EAACI recently updated its privacy policy and would like to highlight some key bits of information with you.

  • EAACI does not distribute, share or sell your information;
  • For technical and administrative purposes some information that can be used to identify you may be forwarded to third parties. For example, to process your registration for the EAACI Annual Congress and other EAACI events;
  • The Academy may also send you e-mail messages with news from the society. If you would like to no longer receive them, you can unsubscribe at any time by using the unsubscribe link in any of our communications;
  • You may also update your preferences or your profile information at any time by contacting us.

To continue please confirm that you agree with our updated privacy policy.

Thank you!

You have successfully agreed the new privacy policy – disclaimer.

Thank you!

You disagreed with the new privacy policy – disclaimer and your feedback will be reviewed as soon as possible.

Agree & Continue
Disagree
Send feedback
Cancel